Comparative Study Between Serological and Molecular Diagnosis test for HBV and HCV in Chronic Renal Failure Patients on Hemodialysis in Nineveh Government/Iraq

Abstract

Patients under hemodialysis treatment for chronic renal failure (CRF) are among the groups with the highest prevalence of hepatitis B and C viruses due to frequent blood transfusion and nosocomial transmission. A group of CRF patients living in Nineveh governments were tested with serological markers for hepatitis B and C using the ELISA Enzyme linked immunosor bent Assay test and Polymerase Chain Reaction (PCR). The validity parameters for the serological results were measured based on the PCR results. Of the 62 patients on hemodialysis during the study, 13 (21%) were HBsAg positive, 49 (79%) were anti-HBS positive 8 (61.5%) were anti-HBC positive and 16 (25.8%) were anti-HCV positive, the PCR tests results in 13 (21%) HBV-DNA positive, the mean viral load were 78950 copy/ml and 15 (24.1%) were HCV-RNA positive the mean viral load were 125000 copy/ml, the accuracy, sensitivity and specificity of Elisa for HBsAg were 90.6%, 50% and 94.8%, and the same parameters were 92.6%, 87.5% and 92.9% for anti-HCV. Based on the results just the negative predictive value for anti-HCV (98.2%) is reliable test in CRF patients on hemodialysis tests are the indicated methodology to diagnosis HBV and HCV infection in these patients. Serological and/or molecular tests are the indicated methodology to diagnosis HBV and HCV infection in these patients.